Bruno LAVIOLLE | Produits de santĂŠ | Best Researcher Award

Posted on by ScienceFather

Prof. Bruno LAVIOLLE  –  Produits de santĂŠ(Health products) – Best Researcher Award

Alignment with Award Category

Professor Laviolle’s sustained research excellence, commitment to teaching and mentoring, and innovative contributions to clinical pharmacology make him exceptionally well-suited for the Best Researcher Award or a category recognizing Excellence in Translational Research or Methodological Innovation.

CHU de Rennes | France

Profile
scopus

🎓Early Academic Pursuits 

Education and Training

Born with a passion for science and healthcare, Bruno LAVIOLLE, MD, PhD (N° d’ordre : 35/5922; N° RPPS : 10002677705) embarked on a rich and rigorous academic journey in the biomedical sciences. His academic foundations were laid with a Bachelor in Science during 1997-98, encompassing Biostatistics, Informatics and Modelling at Nantes University, alongside Methods in Clinical Epidemiology and Clinical Research, and Cellular Pharmacology, Pharmacogenetics, and Pharmacokinetics at Rennes 1 University. Driven by a commitment to clinical excellence, he obtained a Master’s in Human Science with a specialization in Fundamental and Clinical Pharmacology from Paris 11 University in 2002. In the same year, he also earned a Certificate in Public Health from Rennes 1 University, setting the stage for a multidimensional understanding of medicine and pharmacology. He achieved his Medical Doctor degree in 2003, followed by certification in Clinical Pharmacology and Therapeutic Research in 2004. His thirst for research culminated in a PhD in 2011 and an Accreditation to Supervise Doctoral Research in 2013, both from Rennes 1 University.

💼Professional Endeavors 

Academic Positions

Professor Bruno Laviolle currently holds multiple influential positions. He serves as a Professor of Clinical Pharmacology at Rennes 1 University and Rennes University Hospital, where he is also Director of the Clinical Investigation Centre, Inserm 1414, located at HĂ´pital de Pontchaillou in Rennes, France. His dual affiliation with Inserm UMR_S 1085 (Irset) and the Clinical Investigation Centre (Inserm 1414) underscores his central role in bridging translational research and clinical pharmacology. Through these institutions, he plays a crucial role in developing and managing pharmacological studies, advancing medical therapies, and training future experts in the field.

📚Contributions and Research Focus on Produits de santé(Health products)

Bruno Laviolle’s research lies at the intersection of clinical pharmacology, cardiovascular pharmacology, and clinical investigation methodologies. His work is characterized by robust biostatistical modeling, rigorous methodologies for clinical trials, and deep expertise in pharmacokinetics and pharmacodynamics. He is especially recognized for his efforts in clinical investigations in cardiovascular pharmacology, an area where his contributions have had meaningful impacts on patient care and drug safety. As the Director of Inserm 1414, he spearheads major clinical trials and translational research projects. His commitment to scientific excellence extends into education, where he leads the Master’s Course of Clinical Research at Rennes University. Additionally, he is actively involved in training medical and graduate students in clinical trial methodology, pharmacological modeling, and biostatistics, equipping the next generation of healthcare professionals with vital research competencies.

🏆Accolades and Recognition 

Professor Laviolle’s remarkable career is supported by his membership in esteemed organizations. He is a valued member of the French Society of Pharmacology and Therapeutics, the European Association for Clinical Pharmacology, and the American College of Clinical Pharmacology, where he serves on the education committee. Furthermore, his membership in the French Association of Medical School Teachers of Pharmacology highlights his respected position in the academic community. These affiliations reflect the high regard in which his peers hold his clinical, academic, and research contributions. His dedication to education and public health has earned him numerous accolades and sustained recognition in both national and international medical communities.

🌍 Impact and Influence 

Community Impact

The impact of Bruno Laviolle’s work reverberates through both clinical practice and academic circles. His influence is evident in the curriculum he has helped shape for medical students and Master’s level scholars at Rennes University, particularly in critical reading of scientific publications, clinical biostatistics, and pharmacological modeling. Through his leadership at Inserm 1414, he has directly influenced the design and implementation of critical drug trials and research protocols in France and beyond. His dual expertise in clinical medicine and research methodology has positioned him as a key figure in fostering evidence-based clinical practices, particularly in cardiovascular pharmacology and public health intervention trials.

🔮Legacy and Future Contributions 

As a dedicated academic and clinician, Bruno Laviolle has built a legacy of scientific rigor, mentorship, and interdisciplinary innovation. His role in developing comprehensive training programs in clinical pharmacology will continue to influence future generations of researchers and physicians. His ongoing involvement in methodological education and clinical investigation ensures that his impact will not only persist but grow. Looking forward, Bruno Laviolle remains at the frontier of pharmacological research, aiming to deepen the integration of data-driven approaches in clinical medicine, enhance patient outcomes, and refine the tools of modern pharmacology. His dedication to mentoring doctoral students and contributing to global scientific dialogue guarantees a lasting footprint in the field.

Conclusion

Bruno Laviolle, MD, PhD, exemplifies the ideals of a physician-scientist: one who bridges theory with practice, research with application, and knowledge with teaching. From his early academic strides through a rich tapestry of multidisciplinary education, to his current role as a Professor of Clinical Pharmacology and Director of Inserm 1414, his career is marked by excellence, innovation, and influence. Whether through his leadership in clinical investigation, his involvement in international pharmacological associations, or his passion for education, Professor Laviolle has significantly shaped the modern landscape of clinical pharmacology. His work not only enhances the effectiveness and safety of therapeutic interventions but also inspires a new generation of clinical researchers and pharmacologists in France and around the world.

📚Publications

Trends of Publication of Negative Trials Over Time

 Authors: B., Laviolle, Bruno, C., Locher, Clara, J.S., Allain, Jean Sebastien, … É., Bellissant, Éric, F., Naudet, Florian

Journals: Clinical Pharmacology and Therapeutics

Day-to-day dynamics of fetal heart rate variability to detect chorioamnionitis in preterm premature rupture of membranes

Authors: A., Taoum, Aline, G., Carrault, Guy, C., Tesson, Caroline, … B., Laviolle, Bruno, L., Lassel, Linda

Journals: PLoS ONE

Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants

Authors: M., Chalouni, Mathieu, P., Loubet, Paul, E., Lhomme, Edouard, … O., Launay, Odile, L., Wittkop, Linda

Journals: BMC Infectious Disease

Development and validation of a community acquired sepsis-worsening score in the adult emergency department: a prospective cohort: the CASC score

Authors: F., Saget, François, A., Maamar, Adel, M., Esvan, Maxime, … N., Peschanski, N., B., Laviolle, Bruno

Journals: BMC Emergency Medicine

Vladimir Badmaev | Pharma | Industry Impact Award

Posted on by ScienceFather

Dr. Vladimir Badmaev  –  Pharma  –  Industry Impact Award

Alignment with Award Category

Dr. Badmaev’s research and innovations align seamlessly with the Industry Impact Award criteria. His pioneering work in natural pharma and smart drug development, along with his numerous patents and product contributions, make him a highly deserving candidate.

American Medical Holdings Inc. | United States

Profile

Orcid

Scopus

🎓Early Academic Pursuits 

Education and Training

Vladimir Badmaev, MD, PhD, embarked on his academic journey at the Medical Academy of Bialystok (AMB) in Poland, where he graduated in 1975. His early academic years laid a strong foundation in medical sciences, leading him to specialize in clinical and anatomical pathology. He pursued his specialization at Kings County Hospital, New York, and Downstate Medical Center, New York, between 1982 and 1985. During this period, he honed his expertise in understanding disease mechanisms and diagnostic techniques. Additionally, in 1978, he obtained his PhD in immunopharmacology from AMB, reflecting his deep interest in the interaction between the immune system and pharmacological agents. His academic credentials positioned him as a leader in integrative medicine, combining traditional knowledge with scientific advancements.

💼Professional Endeavors 

Academic Positions

Dr. Badmaev’s professional career has been defined by his dedication to bridging traditional botanical medicine with modern pharmacological science. In 1984, he established the Badmaev Natural Drug Foundation, an organization committed to exploring the therapeutic potential of natural compounds. Later, in 2009, he founded American Medical Holdings Inc. in Staten Island, New York, to advance the development of nutraceuticals and natural pharmaceutical products. Through these initiatives, he has played a crucial role in integrating the principles of traditional medicine with contemporary scientific research. His company, www.badmaevtradition.com, stands as a testament to his lifelong commitment to safe and effective alternative medicine solutions.

📚Contributions and Research Focus on Pharma

Dr. Badmaev has dedicated his career to the research and development of nutraceuticals and natural pharmaceutical products. He conceptualized the Interactive Nutrients Process (INP), a method that integrates the knowledge of botanicals with pharmacological science to develop “smart drugs” using artificial intelligence. His work has been instrumental in the advancement of various nutraceutical formulations, including C3Complex® (Sabinsa), Gugulipid® (Sabinsa), SeleniumSelect® (Sabinsa), Lactospore® (Sabinsa), Xanthigen® (PLThomas), RhodioLife® (PLThomas/Polyphenoles Naturales), Zembrin® (PLThomas/HGH), 5-Loxin®/Apres-Flex® (PLThomas), and MenaQ7® (NattoPharma). Furthermore, he has been actively involved in developing natural therapeutics such as Adaptrin®, GreenSelenium®, TurmericImmune®, SlimTrym®, and FB3® under American Medical Holdings Inc. His recent work focuses on the natural ginger phenolic derivative, 6-Shogaol, for managing iron overload and early-stage myelodysplastic syndromes (MDS). This breakthrough has resulted in a US patent, No.: US 10,864,174 B2 (2017), along with 11 related patents worldwide (2017-2024).

🏆Accolades and Recognition 

Between 1999 and 2009, Dr. Badmaev was the runner-up or recipient of four New Jersey R&D Council Thomas Alva Edison Awards. These accolades were awarded in recognition of his contributions to scientific research and patent innovations, including US patents #5,536,506, #5,804,596, #6,849,645, and #7,063,861. His extensive work in the field of nutraceutical research has earned him international recognition, leading to collaborations and multiple patent approvals in various countries, including Australia, Canada, New Zealand, Mexico, Brazil, South Africa, the European Community, Japan, Korea, India, and China.

🌍 Impact and Influence 

Community Impact

Dr. Badmaev’s influence extends beyond research and development. His contributions to literature have enriched the understanding of traditional medicine’s integration with modern healthcare. In 1999, he authored a chapter on Tibetan medicine in a medical textbook for students and healthcare professionals, edited by Wayne Jonas and Jeffrey Levine. A decade later, in 2009, he contributed to a chapter on curcuminoids in a book on alternative treatments in medicine by Raymond Cooper and Fredi Kronenberg. His scholarly work has provided valuable insights into the therapeutic applications of botanical medicine.

🔮Legacy and Future Contributions 

Dr. Badmaev’s contributions have left a lasting impact on the field of integrative medicine. His membership in esteemed medical and scientific societies, including the International Society of Immunopharmacology (1982), the American Association of Clinical Pathologists (1983), the American Medical Association (1984), and the Research and Development Council of New Jersey (1996), underscores his commitment to advancing medical science. His ongoing research into the development of AI-driven “smart drugs” signifies his vision for the future of medicine.

 

Conclusion

Vladimir Badmaev, MD, PhD, has dedicated his career to harmonizing traditional botanical medicine with scientific innovation. His pioneering research, extensive patent portfolio, and contributions to the nutraceutical industry exemplify his lifelong mission to develop safe and effective medical solutions. As he continues his work on AI-integrated nutraceuticals, his legacy serves as an inspiration for future generations in the field of integrative medicine.

📚Publications

Interactive Nutrient Process (INP) in a Generative AI of a New Drug—6-Shogaol as a Potential Case

Authors: Vladimir Badmaev

Journals: Drug Design, Development and Therapy

Vitamin K Insufficiency in the Indian Population: Pilot Observational Epidemiology Study

Authors: Rama Vaidya; Ashok D B Vaidya; Jayesh Sheth; Shashank Jadhav; Umakant Mahale; Dilip Mehta; Janusz Popko; Vladimir Badmaev; Sidney J Stohs

Journals: JMIR Public Health and Surveillance

Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review

Authors: Soo Liang Ooi; Ron Campbell; Sok Cheon Pak; Terry Golombick; Arumugam Manoharan; Raj Ramakrishna; Vladimir Badmaev; Janet Schloss

Journals: Integrative Cancer Therapies

Proof‐of‐Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase‐4 in Cognitively Healthy Subjects: Implications for Alzheimer’s Dementia

Authors: Simon Chiu; Nigel Gericke; Michel Farina-Woodbury; Vladimir Badmaev; Hana Raheb; Kristen Terpstra; Joalex Antongiorgi; Yves Bureau; Zack Cernovsky; Jirui Hou et al.

Journals: Evidence-Based Complementary and Alternative Medicine